Description
Retatrutide 40mg Pen is a research-focused peptide product presented in a pen-format presentation with a stated total quantity of 40mg.
Retatrutide, also known as LY3437943, is an investigational single-molecule triple hormone receptor agonist that acts at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. It is currently being evaluated in Phase 3 clinical research programmes, making its molecular characteristics and receptor activity an ongoing area of scientific investigation.
The compound provides a research model for investigating peptide structure, receptor-related activity, molecular characterisation and analytical properties. Retatrutide is also being studied across several clinical research programmes, including investigations involving obesity, type 2 diabetes and other cardiometabolic conditions.
The Retatrutide 40mg Pen is presented within the AlluviLabsUK research catalogue with an emphasis on clear product identification, structured scientific information and research-focused documentation.
Product Information
- Product: Retatrutide 40mg Pen
- Compound: Retatrutide
- Research identifier: LY3437943
- Stated quantity: 40mg
- Format: Pen
- Category: Research Peptide / Research Compound
- Research areas: Peptide chemistry, molecular research, receptor research and analytical research
- Brand: AlluviLabsUK
Research Use Only
This product is presented for legitimate research and laboratory purposes only, subject to applicable laws and regulations. It is not intended for human or veterinary use or administration, and is not intended to diagnose, treat, cure or prevent any disease. Retatrutide remains an investigational compound and is not currently approved for public use.
Reviews
There are no reviews yet.